09 July 2019
PIDs included in WHO List of Essential Diagnostic Tests
Primary immunodeficiency (PID) diagnostic tests have been included in the World Health Organization (WHO)’s Essential Diagnostics List (EDL) published by WHO on July 9, 2019.
The second publication of the Model List of Essential In Vitro Diagnostics*, also called Essential Diagnostics List (EDL), now includes a new disease-specific section on primary immunodeficiencies (PIDs) as well as a mention of PIDs, in general, for clinical laboratory diagnosis (for more information see here).
Epimune is dedicated to improving early detection of PID by developing in-vitro diagnostic tests for lymphoycyte enumeration from a drop of (dried) blood.
20 May 2019
Epimune wins funding from the German Federal Ministry of Education and Research (BMBF) to support R&D of molecular diagnosis and prognosis of Non-Hodgkin Lymphoma
Together with researchers from the Martin Luther University Halle-Wittenberg, Epimune will explore application of its proprietary epigenetic immune cell quantification technology for the early diagnosis, prognosis and monitoring of patients with B-cell Non-Hodgkin Lymphoma. The 3-year project is funded by the German Federal Ministry of Education and Research (BMBF) with a total of 925,000 €
01 Apr 2019
Epimune appoints Dr. Uwe Staub as Chief Executive Officer (CEO)
Dr. Staub has 25 years of experience in the in-vitro diagnostic (IVD) industry. Before joining Epimune, he was part of Epigenomics' executive team, and held senior management positions at Qiagen, Digene and Abbott
18-21 Sep 2019
06-08 Nov 2019